间充质干细胞来源外泌体与肺动脉高压

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1182 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肺动脉高压是一种具有高致残率和致死率的疾病，其主要病理特征是肺动脉平滑肌增生、肺血管重构。外泌体（EXOs）是一种纳米级胞外囊泡，它能够通过在细胞间传递蛋白质、脂质或RNA起到沟通细胞的作用。近年研究表明，间充质干细胞（MSCs）来源EXOs作为一种新型治疗载体在许多疾病中能够有效发挥治疗作用。笔者就近年来MSCs来源EXOs与肺动脉高压的相关研究进行综述，以期为今后利用EXOs治疗肺动脉高压提供思路。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄菲菲
	王良兴
	黄晓颖

关键词 ：肺动脉高压, 间充质干细胞, 外泌体, 综述文献

PACS:

基金资助:浙江省大学生科技创新活动计划（新苗人才计划）资助项目（2017R413074）

通讯作者: 黄晓颖，主任医师，教授，硕士生导师，Email：zjwzhxy@126.com

作者简介: 黄菲菲（1992-），女，浙江温州人，硕士生

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2018/V48/I1/76

[1] HARDING C, HEUSER J, STAHL P. Receptor-mediated en-

docytosis of transferrin and recycling of the transferrin recep-

tor in rat reticulocytes[J]. J Cell Biol, 1983, 97(2): 329-339.

[2] 冯影, 卢士红, 王昕, 等. 人骨髓来源间充质干细胞分泌外泌体特性研究[J]. 中国实验血液学杂志, 2014, 22(3): 595-599.

[3] LEE C, MITSIALIS S A, ASLAM M, et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension[J]. Circulation, 2012, 126(22): 2601-2611.

[4] FLESHNER M, CRANE C R. Exosomes, DAMPs and miRNA: Features of stress physiology and immune homeostasis [J]. Trends Immunol, 2017, 38(10): 768-776.

[5] ZHAO W, ZHENG X L, ZHAO S P. Exosome and its roles in cardiovascular diseases[J]. Heart Fail Rev, 2015, 20(3): 337-348.

[6] ALEXANDER M, HU R, RUNTSCH M C, et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin[J]. Nat Commun, 2015, 6: 7321.

[7] TRAJKOVIC K, HSU C, CHIANTIA S, et al. Ceramide triggers budding of exosome vesicles into multivesicular en-dosomes[J]. Science, 2008, 319(5867): 1244-1247.

[8] 曹蕾, 杨迷芳, 平锋锋, 等. 小鼠黑素瘤细胞系分泌的外泌体促进间充质基质细胞增殖和迁移[J]. 中华微生物学和免疫学杂志, 2016, 36(1): 42-47.

[9] ONO M, KOSAKA N, TOMINAGA N, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells[J]. Sci Signal, 2014, 7(332): ra63.

[10] QIAN X, XU C, FANG S, et al. Exosomal microRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection[J]. Stem Cells Transl Med, 2016, 5 (9): 1190-1203.

[11] ROLANDSSON E S, AHRMAN E, PALANI A, et al. Quantitative proteomic characterization of lung-MSC and bone marrow-MSC using DIA-mass spectrometry[J]. Sci Rep, 2017, 7(1): 9316.

[12] 邬伟, 陈晓红, 杨景全, 等. 人参皂苷Rg1对植入痴呆大鼠海马中BMSCs存活、分化的影响及其机制[J]. 温州医科大学学报, 2014, 44(9): 637-640.

[13] HAYNESWORTH S E, BABER M A, CAPLAN A I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha[J]. J Cell Physiol, 1996, 166(3): 585-592.

[14] BABER S R, DENG W, MASTER R G, et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dys-function[J]. Am J Physiol Heart Circ Physiol, 2007, 292(2): H1120- 1128.

[15] LIANG O D, MITSIALIS S A, CHANG M S, et al. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension[J]. Stem Cells, 2011, 29(1): 99-107.

[16] GNECCHI M, HE H, NOISEUX N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional im-provement[J]. Faseb j, 2006, 20(6): 661-669.

[17] JIANG Z, LIU G, MENG F, et al. Paracrine effects of mesenchymal stem cells on the activation of keratocytes[J]. Br J Ophthalmol, 2017, 101(11): 1583-1590

[18] XIN H, LI Y, CHOPP M. Exosomes/miRNAs as mediating cell-

based therapy of stroke[J]. Front Cell Neurosci, 2014, 8: 377.

[19] ARCHER S L, WEIR E K, WILKINS M R. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies[J]. Circulation, 2010, 121(18): 2045-2066.

[20] LEE H, LEE J C, KWON J H, et al. The effect of umbilical cord blood derived mesenchymal stem cells in monocrotaline-induced pulmonary artery hypertension rats[J]. J Korean Med Sci, 2015, 30(5): 576-585.

[21] LEE J C, CHA C I, KIM D S, et al. Therapeutic effects of umbilical cord blood derived mesenchymal stem cell-conditioned medium on pulmonary arterial hypertension in rats[J]. J Pathol Transl Med, 2015, 49(6): 472-480.

[22] LIU J, HAN Z, HAN Z, et al. Mesenchymal stem cell-conditioned media suppresses inflammation-associated overproliferation of pulmonary artery smooth muscle cells in a rat model of pulmonary hypertension[J]. Exp Ther Med, 2016, 11(2): 467-475.

[23] BROCK M, TRENKMANN M, GAY R E, et al. Interleukin-

6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway[J]. Circ Res, 2009, 104(10): 1184-1191.

[24] FRAIDENBURG D R, YUAN J. Hungry for more: autophagy in the pathogenesis of pulmonary arterial hypertension [J]. Circ Res, 2013, 112(8): 1091-1093.

[25] CHEN J Y, AN R, LIU Z J, et al. Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats[J]. Acta Pharmacol Sin, 2014, 35 (9): 1121-1128.

[26] ALIOTTA J M, PEREIRA M, WEN S, et al. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice[J]. Cardiovasc Res, 2016, 110(3): 319-330.

[27] CARUSO P, MACLEAN M R, KHANIN R, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline[J]. Arterioscler Thromb Vasc Biol, 2010, 30 (4): 716-723.

[28] SUENDRA G, MICHELAKIS E D. The metabolic basis of pulmonary arterial hypertension[J]. Cell Metab, 2014, 19(4): 558-573.

[29] ESCUDIER B, DORVAL T, CHAPUT N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial[J]. J Transl Med, 2005, 3(1): 10.

[30] YANG T, MARTIN P, FOGARTY B, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio[J]. Pharm Res, 2015, 32(6): 2003-2014.

[31] LIN L Y, DU L M, CAO K, et al. Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities[J]. Oncogene, 2016, 35(46): 6038-6042.

[32] FURLANI D, UGURLUCAN M, ONG L, et al. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy[J]. Microvasc Res, 2009, 77(3): 370-376.